|
Name |
Aspergillusene A
|
Molecular Formula | C15H22O2 | |
IUPAC Name* |
5-(hydroxymethyl)-2-[(E)-6-methylhept-2-en-2-yl]phenol
|
|
SMILES |
CC(C)CC/C=C(\C)/C1=C(C=C(C=C1)CO)O
|
|
InChI |
InChI=1S/C15H22O2/c1-11(2)5-4-6-12(3)14-8-7-13(10-16)9-15(14)17/h6-9,11,16-17H,4-5,10H2,1-3H3/b12-6+
|
|
InChIKey |
NWPUHDAIOGMKFI-WUXMJOGZSA-N
|
|
Synonyms |
Aspergillusene A; CHEBI:68218; (E)-5-(hydroxymethyl)-2-(6'-methylhept-2'-en-2'-yl)phenol; Aspergillusenes A; CHEMBL1812022; SCHEMBL11893489; DTXSID601189342; Q27136711; 5-(hydroxymethyl)-2-[(2E)-6-methylhept-2-en-2-yl]phenol; 4-[(1E)-1,5-Dimethyl-1-hexen-1-yl]-3-hydroxybenzenemethanol; 1313712-06-9
|
|
CAS | 1313712-06-9 | |
PubChem CID | 53468690 | |
ChEMBL ID | CHEMBL1812022 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 234.33 | ALogp: | 4.1 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 40.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 17 | QED Weighted: | 0.792 |
Caco-2 Permeability: | -4.347 | MDCK Permeability: | 0.00002180 |
Pgp-inhibitor: | 0.014 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.067 |
30% Bioavailability (F30%): | 0.188 |
Blood-Brain-Barrier Penetration (BBB): | 0.971 | Plasma Protein Binding (PPB): | 92.76% |
Volume Distribution (VD): | 3.017 | Fu: | 12.13% |
CYP1A2-inhibitor: | 0.887 | CYP1A2-substrate: | 0.859 |
CYP2C19-inhibitor: | 0.813 | CYP2C19-substrate: | 0.328 |
CYP2C9-inhibitor: | 0.764 | CYP2C9-substrate: | 0.92 |
CYP2D6-inhibitor: | 0.8 | CYP2D6-substrate: | 0.538 |
CYP3A4-inhibitor: | 0.392 | CYP3A4-substrate: | 0.323 |
Clearance (CL): | 9.966 | Half-life (T1/2): | 0.669 |
hERG Blockers: | 0.015 | Human Hepatotoxicity (H-HT): | 0.047 |
Drug-inuced Liver Injury (DILI): | 0.09 | AMES Toxicity: | 0.04 |
Rat Oral Acute Toxicity: | 0.111 | Maximum Recommended Daily Dose: | 0.197 |
Skin Sensitization: | 0.446 | Carcinogencity: | 0.046 |
Eye Corrosion: | 0.008 | Eye Irritation: | 0.87 |
Respiratory Toxicity: | 0.135 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002943 | 0.614 | D03LGG | 0.321 | ||||
ENC004196 | 0.565 | D0U5CE | 0.321 | ||||
ENC004195 | 0.565 | D06GIP | 0.316 | ||||
ENC002474 | 0.516 | D0T7OW | 0.310 | ||||
ENC003717 | 0.455 | D0U0OT | 0.303 | ||||
ENC004996 | 0.433 | D02ZJI | 0.300 | ||||
ENC000804 | 0.413 | D0K5CB | 0.300 | ||||
ENC004655 | 0.377 | D08HVR | 0.297 | ||||
ENC002564 | 0.371 | D0Y6KO | 0.296 | ||||
ENC004657 | 0.348 | D01WJL | 0.293 |